AlphAIAlphAI — Financial news for AI agents
gurufocus.comOCT 283 min read$GEHC

GE HealthCare (GEHC) Reports Strong Q3 Results Amid Modest Under

GE HealthCare (GEHC) reported Q3 2026 revenue of $5.5B, up 6.2% organically, with adjusted EBIT margin at 16.6%. The company raised full-year guidance and trades at $76.40, deemed 10.2% undervalued by GF Value™. Insider buying and institutional support are noted.

Original reporting
gurufocus.com
Published Oct 28, 2026, 5:56 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 6:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$GEHC
Bullish
high confidence
Mentioned
$GEHC
Relevance
8/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$GEHCBullishMed
01

Why it matters

The earnings beat and valuation gap could attract value‑oriented investors, while modest growth scores temper enthusiasm.

02

Market read

Earnings release provides fresh data for traders; potential short‑term price move.

03

What to watch

Financial strength and growth scores are only middling, indicating potential downside risks.

Relevance 8/10Novelty 8/10Timing: post‑market today

Background

GE HealthCare reported Q3 2026 results with strong revenue growth and raised guidance, highlighted by GuruFocus valuation metrics.

Company-level read

Ticker impact

$GEHCBullishHigh confidence
Context

Q3 2026 results: 6.2% organic revenue growth, $5.5B revenue, raised full-year guidance and 10% valuation upside.

Expected impact

likely upward pressure as market prices in the valuation gap and higher guidance.

Evidence & confidence

First report of earnings with fresh numbers for a large‑cap health‑tech company; valuation metrics indicate the stock is undervalued.

Market effects

Sector

Positive earnings may lift broader medical‑devices and health‑technology sector.

Regional

U.S. healthcare stocks could see modest gains.

Global

Limited to healthcare sector; no major macro impact.

Counterpoint

What could challenge this read

Valuation upside may already be priced in; growth metrics remain modest.

Key entities

  • company
    GE HealthCare Technologies Inc

    Large‑cap medical‑devices and diagnostics firm.

  • executive
    Peter Arduini

    CEO who highlighted demand trends.

Read at source← All news

StoryGE HealthCare posts strong Q3 2026 results and lifts full‑year guidance

Also covered by

5 outlets

Related articles

OCT 28
$GEHCMed

GE HealthCare Technologies Inc. Q3 2026 Earnings Call Summary

GE HealthCare Technologies Inc. reported Q3 2026 earnings, raising full-year guidance for revenue growth, margins, and cash flow. The company highlighted operational improvements, strategic acquisitions, and supply chain resilience. Management expects continued momentum in 2027 despite inflation and tariff challenges, with a 14% dividend increase. Key growth areas include Advanced Imaging Solutions and Pharmaceutical Diagnostics, with a focus on high-margin products and emerging markets.

finance.yahoo.com2 min
OCT 28
$GEHCHighAI 9/10

GE HealthCare (GEHC) Q3 2026 Earnings Call Transcript

GE HealthCare (GEHC) reported Q3 2026 revenue of $5.5B, up 6.2% organically, with adjusted EBIT margin expanding to 16.6%. Growth was seen across all segments, with pharmaceutical diagnostics leading at 13.8%. The company announced the acquisition of SoFi Bioscience and a leadership change in the Patient Care Solutions business. Free cash flow was $793M, up $310M year-over-year.

finance.yahoo.com3 min
OCT 28
$GEHCHighAI 8/10

GEHC Q3 Earnings Beat Estimates on Strong Growth, '26 View Raised

GE HealthCare (GEHC) reported Q3 2026 adjusted EPS of $1.34, beating estimates by 10.7% and rising 25.1% YoY. Revenue grew 7.2% to $5.51B, exceeding expectations. The company raised its 2026 guidance, forecasting 4% organic revenue growth and adjusted EPS of $4.95-$5.05. Shares rose 8.3% in pre-market trading.

zacks.com3 min
OCT 28
$GEHCHighAI 8/10

GE HealthCare (GEHC) stock trades up, here is why

GE HealthCare (GEHC) stock rose 7.2% after Q3 2026 results beat expectations, with revenue up 7.2% and EPS up 39.1%. The company raised its full-year guidance, citing strong demand for healthcare equipment. GEHC is down 7.8% YTD but up 27.2% since its IPO.

tradingview.com2 min